Managing HTAD: Key Insights from the 2024 ESC Guidelines
1:00:41
Lipoprotein(a): An ASCVD Risk Factor That Can No Longer Be Ignored
42:17
Aortic Diseases | Clinical Medicine
26:28
Atrial fibrillation: What’s new in the 2024 ESC guidelines
1:01:41
Différences de manifestations des syndromes de Marfan, Ehlers-Danlos et Loeys-Dietz
3:54:38
Optogenetics: Illuminating the Path toward Causal Neuroscience
46:42
Valvular Heart Diseases | Clinical Medicine
59:37
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
1:12:02